Overexpression of MTHFD2 represents an inflamed tumor microenvironment and precisely predicts the molecular subtype and immunotherapy response of bladder cancer
Xiaokai Shi, Xiangrong Peng, Yin Chen, Zebin Shi, Chuang Yue, Li Zuo, Lifeng Zhang, Shenglin Gao · 2023
Read Overexpression of MTHFD2 represents an inflamed tumor microenvironment and precisely predicts the molecular subtype and immunotherapy response of bladder cancer by Xiaokai Shi, Xiangrong Peng, Yin Chen, Zebin Shi, Chuang Yue, Li Zuo, Lifeng Zhang, Shenglin Gao (2023) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-10733511.txt.
Description
Xiaokai Shi and co-authors study an enzyme as a marker in bladder cancer in a 2023 paper. The enzyme, MTHFD2, is often overproduced in cancers and may shape immune response. Using large public cancer data, the team asked whether its level in bladder tumors tracks the immune state of the tumor and predicts who gains from immune therapy.
Tumors with high levels showed the marks of an inflamed setting: active immune cycles, more immune cells inside, and higher scores for T cell activity. Such patients were more often of a subtype that responds to treatment and did better on immune therapy in a trial cohort, with higher response rates and longer survival. The authors propose the enzyme level as a guide for choosing therapy in this cancer.
Catalog record
| CREATOR | Xiaokai Shi, Xiangrong Peng, Yin Chen, Zebin Shi, Chuang Yue, Li Zuo, Lifeng Zhang, Shenglin Gao |
|---|---|
| YEAR | 2023 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 40 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |